
	Where results make sense

Topic: Adriamycin

In the News (Sun 27 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	Lymphoma Information Network - Adriamycin / Doxorubicin
		Adriamycin (generic name doxorubicin) is a common chemotherapy agent in the treatment of Hodgkin's Lymphoma / Disease and Nonhodgkin's Lymphoma.
		It is is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var.
		As such, it is an antineoplastic - adriamycin interferes with the growth of cancer cells.
	www.lymphomainfo.net /therapy/drugs/adriamycin.html (517 words)

	Adriamycin-induced DNA Adducts Inhibit the DNA Interactions of Transcription Factors and RNA Polymerase -- Cutts et al. ...
		Although the reactivities of adriamycin with a range of cellular constituents are well known, the specific cellular mechanisms involved and the ultimate cause of tumor cell death are still to be elucidated.
		At 10 µM adriamycin, the binding of Oct-1, N-Oct-3, and N-Oct-5 is inhibited by approximately 25, 40, and 30% respectively (Fig.
		Although adriamycin has been a major inclusion in chemotherapy regimes for 20 years and appears to act as a topoisomerase II inhibitor, a major research effort is still required directed toward elucidating its basic modes of action in tumor tissue.
	www.jbc.org /cgi/content/full/271/10/5422 (5674 words)

	Adriamycin, Doxorubicin, Rubex Chemotherapy Drugs (Site not responding. Last check: 2007-10-08)
		Adriamycin is given through a vein by intravenous injection (IV).
		Adriamycin can also be given by continuous infusion.
		The amount of adriamycin you will receive depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer you have.
	www.chemocare.com /BIO/adriamycin.asp (1549 words)

	Adriamycin® (doxorubicin) Client information Sheet
		Adriamycin® (doxorubicin) is a broadspectrum chemotherapy drug used to fight many forms of cancer and has been used for decades.
		Adriamycin® is an orange-red liquid, which is diluted and painlessly administered directly into a vein.
		Should your pet have an allergic reaction to Adriamycin®, it would develop upon administration, and your veterinarian and the hospital staff are trained to treat patients for allergic reaction.
	www.vspn.org /Library/Misc/VSPN_M02526.htm (1101 words)

	Adriamycin
		Adriamycin, an active medicine against many cancers, is one of the older chemotherapy drugs, having been in use for decades.
		Adriamycin is a clear, orange-red colored powder or liquid, which is administered intravenously only.
		Adriamycin may be administered as a continuous intravenous infusion over a span of four to five days,, or given on a scheduled basis, i.e., once a week or once every three to four weeks, etc.)
	www.tirgan.com /adria.htm (185 words)

	Adriamycin (Site not responding. Last check: 2007-10-08)
		Adriamycin is a type of antibiotic used specifically in the treatment of cancer.
		Adriamycin may cause severe nausea and vomiting that can be managed with medications.
		Adriamycin can lower the number of white blood cells produced for fighting infections and platelets for clotting the blood.
	www.bmi.net /mcaron/adria.html (453 words)

	Adriamycin - Full Prescribing Information
		ADRIAMYCIN PFS and ADRIAMYCIN RDF impart a red coloration to the urine for 1 to 2 days after administration, and patients should be advised to expect this during active therapy.
		ADRIAMYCIN RDF 10 mg, 20 mg, 50 mg, and 150 mg vials should be reconstituted with 5 mL, 10 mL, 25 mL, and 75 mL, respectively, of Sodium Chloride Injection, USP (0.9%), to give a final concentration of 2 mg/mL of doxorubicin hydrochloride.
		It is recommended that ADRIAMYCIN PFS and ADRIAMYCIN RDF be slowly administered into the tubing of a freely running intravenous infusion of Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP.
	www.meds.com /leukemia/idamycin/adriamycin.html (3883 words)

	Molecular Basis for the Synergistic Interaction of Adriamycin with the Formaldehyde-releasing Prodrug Pivaloyloxymethyl ... (Site not responding. Last check: 2007-10-08)
		because the Adriamycin monoadduct is stabilized by the complementary
		Phosphorimage analysis was used to quantitate Adriamycin adducts in the mtDNA of IMR-32 cells (C) and MCF-7 cells (E) and also in the DHFR gene of IMR-32 cells (D) and MCF-7 cells (F).
		is that Adriamycin accumulation in the nucleus and mitochondria
	cancerres.aacrjournals.org /cgi/content/full/61/22/8194 (5406 words)

	Adriamycin - Talk Medical
		Adriamycin interferes with the growth of cancer cells and slows their growth and spread in the body.
		· Adriamycin is in the FDA pregnancy category D. This means that Adriamycin is known to be harmful to an unborn baby.
		Continue taking Adriamycin and talk to your doctor if you experience: ·facial flushing during administration; ·eye irritation or tearing; ·darkening of the nail beds and skin folds; ·temporary hair loss; or ·red colored urine for 1 or 2 days following a dose.
	www.talkmedical.com /medications/118/Adriamycin (930 words)

	News - Suramin/Adriamycin Appears Active In Hormone Refractory Prostate Cancer: Presented at AACR (Site not responding. Last check: 2007-10-08)
		Guangzhi Qu, MD, a fellow in oncology at the Mayor Clinic, in Rochester, Minnesota, said that four of 16 patients with advanced prostate cancer had partial responses to the treatment-meaning that prostate specific antigen (PSA) levels dropped by at least 50 percent or that tumors decreased in size by 50 percent.
		The 24 patients who received the dose-escalating regimen of adriamycin while receiving a dose-lowering schedule of suramin had various types of advanced cancer, but the only partial responses seen were in those patients with prostate cancer.
		Adriamycin was dosed a 10 mg for the first patients in the study, and was increased to 60 mg for the last patients entered into the study.
	docguide.com /news/content.nsf/news/8525697700573E1885256B95004CBD41 (539 words)

	Cyclophosphamide, adriamycin, 5-fluorouracil and high-dose toremifene for patients with advanced/recurrent breast ...
		Cyclophosphamide, adriamycin, 5-fluorouracil and high-dose toremifene for patients with advanced/recurrent breast cancer.
		Additionally, in preclinical studies, the combination of high-dose TOR and adriamycin (ADM) was found to be effective for tumors with cells resistant to ADM (13).
		In this preliminary trial, to examine the toxicity and efficacy of a new chemoendocrine therapy, we administered a combination of cyclophosphamide, adriamycin and 5-fluorouracil (CAF therapy) with high-dose TOR to patients with advanced/recurrent breast cancer.
	jjco.oxfordjournals.org /cgi/content/full/28/4/250 (2060 words)

	Activation of Adriamycin by the pH-dependent Formaldehyde-releasing Prodrug Hexamethylenetetramine -- Swift et al. 2 ...
		End-labeled DNA was incubated in the presence of Adriamycin
		bp) was incubated with Adriamycin and either formaldehyde or HMTA (as a source of formaldehyde) until approximately 70% dsDNA resulted at 37°C. Aliquots were then taken at 0, 1, 2, 4, 6, 8, 12, 24, and 36 h, and the residual lesions were determined by electrophoretic analysis.
		Cells were treated with varied concentrations of Adriamycin, HMTA, and a combination of both drug and prodrug at 37°C, 5% CO for 72 h.
	mct.aacrjournals.org /cgi/content/full/2/2/189 (5623 words)

	Early Results Show Taxol/Adriamycin Effective In Breast Cancer (Site not responding. Last check: 2007-10-08)
		There were three treatment arms compared: Taxol vs. Adriamycin vs. a combination of Taxol and Adriamycin.
		Some patients who initially received Adriamycin and experienced progression of disease were then placed on Taxol therapy.
		Seven hundred thirty nine patients with recurrent or metastatic breast cancer were randomized to receive Adriamycin (60 mg/m2), Taxol (175 mg/m2/24hr.), or the combination of Adriamycin/Taxol (50 mg/m2/150 mg/G-CSF) in the first line setting.
	www.pslgroup.com /dg/29722.htm (559 words)

	The Blood of Christ, Adriamycin quilt by Ann Stamm Merrell; from Living Outside the Lines
		Included among the side effects of the chemotherapy were nausea, vomiting, total hair loss, low blood counts, loss of appetite and weight, extreme fatigue, breathing difficulty and the need for three transfusions and two hospital stays.
		Adriamycin, the red liquid being injected into my veins, was an extremely powerful and extremely caustic agent coursing through my body.
		Some of the texts for the photo transfer fabrics include: Bible quotes, an FDA data sheet on Adriamycin, a schedule of meals brought in by friends.
	www.ann.stamm.merrell.org /page42.html (600 words)

	Adriamycin impairs the contraction of mesangial cells through the inhibition of protein kinase C and intracellular ...
		Adriamycin impairs the contraction of mesangial cells through the inhibition of protein kinase C and intracellular calcium -- Jin et al.
		Articles by Jin, J.-S. Articles by Chen, A. Adriamycin impairs the contraction of mesangial cells through the inhibition of protein kinase C and intracellular calcium
		Representative cell images of cultured mesangial cells with (Adriamycin) or without (Control) the treatment of adriamycin (0.2 µg/ml) for 24 h in response to 1 µM PMA (Control+PMA; Adriamycin+PMA) for 30 min.
	ajprenal.physiology.org /cgi/content/full/287/2/F188 (3504 words)

	Doxil, A New Type of Adriamycin, Has Fewer Serious Side Effects (Site not responding. Last check: 2007-10-08)
		The risk of Adriamycin causing heart damage is related to how much of it you get overall (the "cumulative" dose).
		Adriamycin has side effects that can be more severe, including hair loss, vomiting, and low white blood cell counts.
		If you have advanced disease and have not tried Adriamycin, or if you've done well on Adriamycin but your doctor says you shouldn't take any more because it might damage your heart, talk to her or him about taking Doxil.
	www.breastcancer.org /research_chemotherapy_doxil.html (1327 words)

	Uncoupling Ceramide Glycosylation by Transfection of Glucosylceramide Synthase Antisense Reverses Adriamycin Resistance ...
		Adriamycin and ceramide toxicity in MCF-7-AdrR and in GCS antisense-transfected MCF-7-AdrR cells.
		Cells were seeded into 96-well plates and treated the following day with adriamycin, at the concentrations shown, in 5% FBS RPMI 1640 medium.
		Cells were treated with increasing concentrations of adriamycin for 48 h and radiolabeled simultaneously during the last 24-h period.
	www.jbc.org /cgi/content/full/275/10/7138 (4780 words)

	Adriamycin-Induced Early Changes in Myocardial Antioxidant Enzymes and Their Modulation by Probucol -- Li and Singal ...
		Effects of adriamycin (ADR) and probucol (PROB) on myocardial antioxidant enzyme activities at 1, 2, 4, and 24 hours after last injection.
		Effects of adriamycin and probucol on myocardial lipid peroxidation examined as TBARS.
		Adriamycin stimulates low-affinity Ca binding and lipid peroxidation but depresses myocardial function.
	circ.ahajournals.org /cgi/content/full/102/17/2105 (3599 words)

	Lymphoma Information Network - ABVD Chemotherapy
		Adriamycin, Bleomycin, and Vinblastine are usually given as follows: you have a saline intravenous drip and the drugs are injected into the IV tube while receiving the saline).
		Dacarbazine is given commonly by a chemotherapy pump which can administer a fixed rate of the drug.
		Adriamycin and Vinblastine may cause kidney problems and liquids may help.
	www.lymphomainfo.net /therapy/chemotherapy/abvd.html (955 words)

	Baroreflex Sensitivity and Oxidative Stress in Adriamycin-Induced Heart Failure -- Rabelo et al. 38 (3): 576 -- ...
		adriamycin for a cumulative dose of 13 mg/kg in 6 injections
		Inverse correlation obtained by linear regression in control and adriamycin groups; B, between tachycardic index (bpm/mm Hg) and chemiluminescence (cps/mg protein); and C, bradycardic index and left ventricle end diastolic pressure (mm Hg).
		Chronic adriamycin treatment and its effects on the cardiac ß-adrenergic system in the rabbit.
	hyper.ahajournals.org /cgi/content/full/38/3/576 (2479 words)

	ASCO MEETING: Taxotere Plus Adriamycin Outperforms Standard Combination In Breast Cancer (Site not responding. Last check: 2007-10-08)
		The study included 429 women with documented metastatic breast cancer who had not undergone prior chemotherapy for metastatic disease and had not received a prior anthracycline-containing regimen as adjuvant and/or neo-adjuvant chemotherapy.
		The regimen was repeated every three weeks for a maximum of eight cycles without the use of prophylactic colony-stimulating factors (agents used to strengthen the body's ability to fight infection) or antibiotics, except following an episode of neutropenia (a low white blood cell count).
		Of particular note, the rate of cardiac toxicity for the two treatment combinations did not exceed that expected with the total cumulative doses of Adriamycin given.
	www.pslgroup.com /dg/fe22a.htm (962 words)

	Synergistic Activity of Recombinant Human Endostatin in Combination with Adriamycin: Analysis of in Vitro Activity on ...
		Synergistic Activity of Recombinant Human Endostatin in Combination with Adriamycin: Analysis of in Vitro Activity on Endothelial Cells and in Vivo Tumor Progression in an Orthotopic Murine Mammary Carcinoma Model -- Plum et al.
		Interestingly, Adriamycin at 100, 10, 1, 0.1, and 0.01
		Adriamycin treatment regimens as a means to improve the clinical
	clincancerres.aacrjournals.org /cgi/content/full/9/12/4619 (4435 words)

	Responses - Adriamycin — Chemotherapy Medication (Site not responding. Last check: 2007-10-08)
		Michael E. Shy, M.D., Wayne State University School of Medicine, Detroit, MI Unfortunately, data on the effects of many medications such as Adriamycin are lacking, so it is difficult to give a definitive answer to this issue.
		My suspicion is that the changes you observe in your son may be related to Vincristine, if this was part of the initial regimen (if I understood you correctly).
		To my knowledge there are no clear reports associating Adriamycin with CMT exacerbations in the literature though this issue is presently being investigated in various CMT databases.
	www.mdausa.org /experts/question.cfm?id=3600&disease=90 (360 words)

	Clinical Trial - A Phase II Study of VAD (Vincristine, Adriamycin, Dexamethasone) plus Thalidomide (low dose) as ...
		To determine the overall response rate (CR+PR) of this novel combination, Thalidomide with VAD (Vincristine, Adriamycin, Dexamethasone) regimen.
		The treatment regimen to be used in this trial is the combination of Thalidomide and VAD (Vincristine, Adriamycin, Dexamethasone).
		Thalidomide will be started at 100mg, every day, orally at bedtime on day 1 of cycle #1 or 2 of VAD and continued for 4 months (or 4 weeks after the 4th cycle of VAD regimen).
	www.multiplemyeloma.org /clinical_trials/ctm/4.04.085.html (258 words)

	Single Dose of Adriamycin Triggers Acute Left Ventricular Failure - CME Teaching Brief - MedPage Today
		Cardiotoxicity is a well-recognized side effect of Adriamycin treatment, but typically heart failure develops over time and is dose dependent.
		This case report suggests that Adriamycin may also trigger acute ventricular failure, and the authors suggest that ventricular function should be assessed in patients who develop pulmonary symptoms after even a single dose of Adriamycin.
		AKRON, June 8-A single 50-mg dose of Adriamycin (doxorubicin) during hepatic artery chemoembolization for a metastatic carcinoid tumor resulted in acute reversible left ventricular failure in a 78-year-old woman, clinicians here reported.
	www.medpagetoday.com /tbindex.cfm?tbid=1167&topicid=78 (411 words)

	Herceptin Without Adriamycin Safer for the Heart (Site not responding. Last check: 2007-10-08)
		Background and importance: Studies in the past showed that the combination of Herceptin and Adriamycin (chemical name: doxorubicin) could weaken the heart muscle, putting a woman at increased risk for congestive heart failure.
		If a woman with breast cancer had a very good response to Adriamycin and Herceptin, but she develops some weakening of the heart, then she needs to stop the medications, at least temporarily.
		The study suggests that if you've had heart trouble with Adriamycin with or without Herceptin, and your heart has gone back to normal, you might be able to start taking Herceptin (or take it again if you already have in the past) without damaging your heart more.
	www.breastcancer.org /research_herceptin_050002a.html (754 words)

	Early Results Show Taxol/Adriamycin Effective In Breast Cancer
		Similarly, some patients who initially received Taxol therapy and had disease progression were placed on Adriamycin.
		For example, the average length of time until disease progression (or time to treatment failure) in a patient on the combination therapy arm was greater than the time to treatment failure on either of the single agent arms.
		Additionally, no greater cardiac toxicity was seen in the combination therapy compared with the single agent therapy, Adriamycin.
	www.docguide.com /dg.nsf/PrintPrint/E9C8246533EE24968525649F005BAD87 (530 words)

	Probucol Protects Against Adriamycin Cardiomyopathy Without Interfering With Its Antitumor Effect -- Siveski-Iliskovic ...
		Inhibition of sodium-potassium activated adenosine 5-triphosphatase and non transport by adriamycin.
		Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response.
		Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity.
	circ.ahajournals.org /cgi/content/full/91/1/10 (3863 words)

	La Trobe University: Department of Biochemistry (Site not responding. Last check: 2007-10-08)
		Swift, L.P., Cutts, S.M., Rephaeli, A. Nudelman, A. and Phillips, D.R. (2003) Activation of Adriamycin by the pH dependent formaldehyde-releasing prodrug hexamethylenetetramine.
		Cutts, S.M., Rephaeli, A., Nudelman, A., Hmelnitsky, I. and Phillips, D.R. (2001) Molecular Basis for the Synergistic Interaction of Adriamycin with the Formaldehyde-releasing Prodrug Pivaloyloxymethyl Butyrate (AN-9).
		Moufarij, M.A., Cutts, S.M., Neumann, G.M., Kimura, K-I. and Phillips D.R. (2001) Barminomycin functions as a potent pre-activated analogue of Adriamycin.
	www.latrobe.edu.au /biochemistry/labs/phillips/publications.html (1078 words)

Try your search on: Qwika (all wikis)